Advertisement
U.S. markets open in 4 hours 24 minutes

CorMedix Inc. (CRMD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
4.1600+0.0500 (+1.22%)
At close: 04:00PM EDT
4.1800 +0.02 (+0.48%)
After hours: 05:34PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close4.1100
Open4.1700
Bid4.1600 x 300
Ask4.2000 x 100
Day's Range4.0598 - 4.2299
52 Week Range2.5700 - 6.0900
Volume370,744
Avg. Volume437,929
Market Cap228.721M
Beta (5Y Monthly)1.85
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for CRMD

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • CorMedix Inc.
    Technical Assessment: Neutral in the Intermediate-TermIt was another week of all-time highs, with the weekly winning streak for the S&P 500 (SPX) continuing. The SPX has moved higher in 17 out of 21 weeks, with a 27% gain during that period. The Nasdaq 100 (QQQ) and the Nasdaq are also 17 out of 21, soaring 30%. The S&P 400 prints the same story, with a 29% pop. Index price volatility is almost undetectable, although there has been some decent volatility, both up and down, among individual stocks. We saw one day of strong breadth on Wednesday and one weak day on Friday.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more